Disruption of normal PYY processing, resulting in reduced PYY (3-36) activity, is associated with increased adiposity and insulin resistance, which can exacerbate hepatic lipid accumulation and promote MASLD progression. Here, PYY is linked to metabolic dysfunction-associated steatotic liver disease.